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Abstract
Background: The anti-inflammatory capacity of heat shock proteins (HSP) has been demonstrated in various animal models
of inflammatory diseases and in patients. However, the mechanisms underlying this anti-inflammatory capacity are poorly
understood. Therefore, the possible protective potential of HSP70 and its mechanisms were studied in proteoglycan (PG)
induced arthritis (PGIA), a chronic and relapsing, T cell mediated murine model of arthritis.
Methodology/Principal Findings: HSP70 immunization, 10 days prior to disease induction with PG, inhibited arthritis both
clinically and histologically. In addition, it significantly reduced PG-specific IgG2a but not IgG1 antibody production.
Furthermore, IFN-c and IL-10 production upon in vitro restimulation with HSP70 was indicative of the induction of an
HSP70-specific T cell response in HSP70 immunized mice. Remarkably, HSP70 treatment also modulated the PG-specific T
cell response, as shown by the increased production of IL-10 and IFN-c upon in vitro PG restimulation. Moreover, it increased
IL-10 mRNA expression in CD4
+CD25
+ cells. HSP70 vaccination did not suppress arthritis in IL-10
2/2 mice, indicating the
crucial role of IL-10 in the protective effect.
Conclusions/Significance: In conclusion, a single mycobacterial HSP70 immunization can suppress inflammation and tissue
damage in PGIA and results in an enhanced regulatory response as shown by the antigen-specific IL-10 production.
Moreover, HSP70 induced protection is critically IL-10 dependent.
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Introduction
Heat shock proteins (HSP) are highly immunogenic and have
the potential to trigger immuno-regulatory pathways. Although
the exact mechanisms of immuno-regulation by HSP remain to be
clarified, T cells specific for HSP were suggested to be involved in
regulation of multiple chronic inflammatory diseases like rheuma-
toid arthritis (RA), diabetes and atherosclerosis [1–4].
Recent studies on HSP-responding T cells of juvenile idiopathic
patients implied a regulatory role and contribution to disease
remission for HSP60-specific T cells [5,6]. Among the various HSP
families of molecules, the immuno-modulatory potential of HSP60
has been studied most extensively. However, also other HSP have
immuno-regulatory functions. For example treatment withbacterial
HSP70 has been shown to protect against development of adjuvant
induced arthritis in rats, whereas treatment with other highly
conserved bacterial proteins did not [7]. Exposure to bacterial HSP
has been shown to activate self HSP-specific T cells that were cross
reactive with bacterial HSP and induced suppression of arthritis
[8,9]. In addition, a T cell line specific for an HSP70-derived
peptide has been described to decrease disease severity upon
transfer [10]. The protective potential of HSP, in animal models,
has been reproduced by recent clinical trials with HSP-derived
peptides in patients [11,12].
Even though HSP induced immuno-regulation has been studied
rather extensively, the mechanism of HSP induced protection in
autoimmune diseases is still not clear. A potential regulatory
mechanism might be via the induction of IL-10 since the important
role of IL-10 in dampening inflammation has been described
extensively [13–15]. Additionally, IL-10 requirement for their
suppressive function has been thought to be a common feature
among most subsets of regulatory T cells as summarized [16].
In the present study the protective potential of mycobacterial
HSP70 immunization on inflammatory disease and its dependency
on IL-10 were assessed in the proteoglycan-induced arthritis
model (PGIA), a progressive T cell dependent, antibody-mediated
murine model for RA [17]. In this model arthritis can be induced
by immunization with human proteoglycan (PG) mixed with
synthetic adjuvant dimethyldioctadecylammonium bromide
(DDA) instead of complete Freund’s adjuvant (CFA) [18].
Therefore, the possibility of interfering with immune responses
induced by mycobacterial HSP present in CFA can be excluded.
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4186We found that HSP70 immunization dramatically suppressed
arthritis development, subsequent tissue damage and the patho-
genic PG-specific antibody response. Moreover, we demonstrate
that HSP70 immunization results in a regulatory T cell response
not only to HSP70, but also to the disease inducing PG. Finally,
HSP70 did not suppress arthritis in IL-10 deficient mice,
indicating that the regulatory response is IL-10 dependent.
Materials and Methods
Mice
Female BALB/c mice, retired breeders aged between 16–
26 weeks, purchased from Charles River (Maastricht, The
Netherlands), and IL-10
2/2 mice also on the BALB/c back-
ground (kindly provided by Dr. D. Reddick, DNAX, Palo Alto,
CA) [19] were bred, housed and fed under standard conditions.
Experiments were approved by the Animal Experiment Commit-
tee of Utrecht University (Utrecht, the Netherlands).
Induction and assessment of arthritis
Arthritis was induced with PG using a standard immunization
protocol as described [17,18]. Briefly, 300 mg PG protein was
given by intra peritoneal injection (i.p) with 2 mg of DDA (Sigma,
Zwijndrecht, the Netherlands) emulsified in 200 ml PBS on days 0
and 21. PG was prepared as described elsewhere [20]. After the
second PG immunization the paws of mice were examined in a
blinded fashion 3 times a week to record arthritic changes of the
joints. The onset and severity of arthritis were determined using a
visual scoring system based on swelling and redness of paws as
described [18]. Upon sacrifice, joints were fixed in 10% buffered
formalin, decalcified in 0.33 M neutralized EDTA, embedded in
paraffin and 5 mm sagittal sections were stained with hematoxylin
and eosin.
HSP70 or control immunization
HSP70 or control immunization was done, 10 days prior to
arthritis induction, by intraperitoneal (i.p.) immunization with
100 mg recombinant HSP70 of Mycobacterium tuberculosis (Mt)
(LIONEX Diagnostics&Therapeutics GmbH, Braunschweig,
Germany), or 100 mg control protein, either recombinant
enhanced green fluorescent protein (EGFP) or ovalbumin (Ova)
(Sigma) in adjuvant DDA, 2 mg emulsified in PBS or with PBS in
a total volume of 200 ml. To avoid interference of LPS
contamination with HSP70 treatment, HSP70 containing less
than 2.1 EU/mg protein was used.
Analysis of PG- and HSP70-specific serum antibody
production
Antigen-specific serum antibody levels were determined by
ELISA as described previously [18]. In brief, 96 well plates
(Corning B.V. Live Sciences, Schiphol Rijk, the Netherlands) were
coated by overnight incubation with 100 ml PG or HSP70 at
5 mg/ml in coating buffer (0.1 M NaHCO3,N a 2CO3 pH 9.6).
Free binding sites were blocked with blocking buffer, Roche
blocking reagents for ELISA (Roche Diagnostics, Alkmaar, the
Netherlands) followed by incubation with sera at increasing
dilutions and subsequently peroxidase-conjugated anti-IgG1, -
IgG2a or -total IgG (BD Pharmingen, Breda, the Netherlands) in
blocking buffer. After ABTS incubation serum PG-specific
antibody levels were calculated as OD relative to the OD
measured for the corresponding isotypes of a standard of pooled
sera from arthritic mice. For HSP70-specific antibody production
a reference serum of HSP70 immunized mice was used. Data were
expressed relative to the average of the control group.
Measurement of antigen-specific T cell responses
Single-cell suspensions of spleens were cultured in triplicates in 96-
well flat bottom plates (Corning B.V.) at 2610
5 cells per well, in the
presence or absence of HSP70 (10 mg/ml), PG (10 mg/ml) or Ova
(10 mg/ml). Iscove’s Modified Dulbecco’s Medium (IMDM) supple-
mented with 10% FCS (Bodinco B.V., Alkmaar, the Netherlands),
2 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml streptomy-
cin, and 5610
25 M 2-mercaptoethanol was used as culture medium.
After 72 or 96 hours, the cells were pulsed overnight with
3H-
thymidine (0.4 mCi per well; Amersham Biosciences Europe GmbH,
Roosendaal, the Netherlands), harvested and
3H uptake was
measured by liquid scintillation counting (Microbeta, Perkin-Elmer
Inc., Boston, MA). Supernatants of antigen stimulated spleen cell
cultures were collected for cytokine assays after 72 hours. Superna-
tants harvested from cultures with cells isolated from WT mice were
analyzed for IL-10 and interferon-gamma (IFN-c)e x p r e s s i o n
simultaneously by multiplex analysis using the Luminex 100 system
(Becton Dickinson, Mountain View,CA).The LINCOplex assay was
performed according to the manufacturer’s instructions (Linco
Research, Inc., St. Charles, Missouri). The concentrations of IL-10
and IFN-c in the supernatants were calculated using LMAT software
(Luminex Corporation, Austin, TX). IFN-c secretion by cells isolated
from IL10
2/2 mice was measured by ELISA (BD OptEIA)
according to manufactures protocol (BD Pharmingen).






+ spleen cells from arthritic mice was
done by staining single cell suspensions of spleen cells with anti-
CD4-allophycocyanin (RM4-5) and anti-CD25 r-phycoerythrin
(PC61) monoclonal antibodies (BD Pharmingen). CD4
+CD25
+ cells
weresortedby CD4and CD25 expression with a FACSVantage SE
(Becton Dickinson). Then total mRNA extraction, with the RNeasy
kit (Qiagen Benelux B.V., Venlo, the Netherlands), on column
DNAse treatment (Qiagen), and transcription into cDNA using the
iScript
TM cDNA Synthesis Kit (Bio-Rad Laboratries B.V.,
Veenendaal, The Netherlands) were carried out according to
manufacturers protocol. PCR (3 min at 95uC and 40 cycles of 10 s
95uC and 45 s at 59.5uC) and Real-Time detection were performed
in a Bio-Rad MyiQ iCycler (Bio-Rad). Amplification was done
using IQ
TM SYBR GreenH Supermix (Bio-Rad) with 0.25 mM final
concentrations of primers specific for IL-10 (59-GGT TGC CAA
GCC TTA TCG GA-39 and 59-ACC TGC TCC ACT GCC TTG
CT-39), Foxp3 (59- CCCAGGAAAGACAGCAACCTT and 59-
TTC TCA CAA CCA GGC CAC TTG-3) and hypoxanthine-
guanine phosphoribosyl transferase (HPRT) (59-CTG GTG AAA
AGG ACC TCT CG and 59-TGA AGT ACT CAT TAT AGT
CAA GGG CA-39). For each sample mRNA expression was
normalized to the detected Ct value of HPRT and expressed
relative to the average of the control group.
Statistical analysis
Unless stated otherwise, data are expressed as mean6standard
error of the mean (SEM). Statistical analysis was carried out using the
Mann-Whitney U test (two-tailed) using Prism software (version 3.00,
Graphpad Software Inc., San Diego). Significance level was set at
(p,0.05).
Results
Immunization with HSP70 decreases arthritis incidence
and severity
To investigate the immuno-regulatory mechanisms of HSP70 in
inflammatory diseases, the effect of mycobacterial HSP70
HSP70 Suppression in PGIA
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HSP70 10 days prior to induction of arthritis by i.p. immunization
with 100 mg HSP70, in the synthetic adjuvant DDA, whereas
control groups received 100 mg EGFP or PBS in DDA.
Subsequently, arthritis was induced by two i.p. immunizations
with PG in DDA on day 0 and 21. HSP70 immunization lowered
the incidence of arthritis and significantly delayed the onset of
arthritis; day 5263.2 in HSP70 immunized mice compared to day
3162.0 in EGFP and 3061.0 in PBS pretreated mice (p,0.01)
(Fig. 1A). Furthermore, HSP70 pre-treatment evidently reduced
severity of PGIA (Fig. 1B). In association, histological analysis of
joint sections of HSP70 immunized arthritic mice showed very
mild leukocyte infiltration, less reactive synovial cell proliferation,
and consequently almost no cartilage damage compared to joint
sections of control animals (Fig. 2A–B).
Altered antigen-specific B cell responses after HSP70
immunization
PG-specific B cell responses have been described to be required
for development of severe PGIA [17]. Therefore, the PG-specific
B cell response and the effect of HSP70 immunization on this
response were studied. On day 38 after the first PG injection PG-
specific serum IgG1 and IgG2a levels were determined by ELISA.
High IgG1 levels confirmed the induction of a B cell response
against the disease inducing PG in both treatment groups.
However, the level of IgG2a was lowered in HSP70 compared
to PBS immunized mice (Fig. 3A). In addition, we studied the
pattern on days 50–64, after development of mild disease in
HSP70 immunized mice. At days 50–64 the difference between
PBS and HSP70 immunized mice in IgG1 levels was comparable
to day 38 but the decrease in IgG2a, as observed on day 38, was
no longer significant (Fig. 3B). The data indicate that mainly the
PG-specific IgG2a production was influenced by HSP70 immu-
nization and underline the importance of this isotype for induction
of PGIA. Recently, HSP-specific antibodies have been shown to
play a role in HSP induced regulation in models for RA [21,22].
To address whether HSP70-specific antibodies were also induced
upon HSP70 immunization in the PGIA model, HSP70 serum
antibody levels were analyzed by ELISA. Significantly increased
HSP70-specific total IgG production was found in HSP70
immunized mice (Fig. 3C). Thus, both PG- and HSP70-specific
B cell responses were altered upon HSP70 treatment as shown by
a decreased pathogenic PG-specific response and an increased,
possibly protective HSP70-specific B cell response.
Increased antigen-specific proliferation, IL-10 and IFN-c
production after immunization with HSP70
In previous studies, HSP-specific T cell responses have been
described to be involved in HSP-induced protection from disease
development [7,9]. To study the effect of HSP70 immunization on
differentiation of antigen-specific T cell responses, PG- and
HSP70-specific proliferation and cytokine profiles were analyzed.
Therefore, spleen cells from HSP70 or PBS immunized mice were
harvested on day 35 after the first PG immunization. Antigen-
specific proliferation was assessed by culturing the isolated cells for
96 hours with PG or HSP70 while Ova was used as control
antigen. During the last 18 hours
3H-thymidine was added and
incorporation was measured and expressed as mean stimulation
index (CPM Antigen/CPM background)6SEM. The mean
background values (responses without antigen) were for the PBS
control group 839062135 and for the HSP70 group
10 18062741. A significantly enhanced proliferative response to
HSP70 restimulation was seen in HSP70 immunized mice as
compared to control mice (Fig. 4A). Remarkably, also the
proliferative response against the arthritis inducing PG was
enhanced in the HSP70 group. Next, antigen-induced production
of IL-10 and IFN-c was studied in supernatants collected after
72 hours culturing in the presence of PG or HSP70. Increased IL-
10 production, by spleen cells from HSP70 immunized mice,
could be detected after HSP70 in vitro restimulation (Fig. 4B).
Interestingly, this increased IL-10 production was also found after
PG in vitro restimulation. Furthermore, the amount of IFN-c
produced by HSP70- and PG-specific cells from HSP70 treated
mice was increased (Fig. 4C). In summary this clearly showed that
HSP70 immunization not only induced an HSP70-specific T cell
response but also modulated the T cell response to the disease
inducing antigen.




It has been proposed that induction or activation of HSP70-
specifc regulatory T cells cross-reactive with self-HSP70 are
involved in protection seen after HSP70 immunization [8,9]. To
study in more detail whether HSP70 immunization influenced
Figure 1. Decreased arthritis incidence and severity after HSP70 immunization. Mice were injected intraperitoneally, 10 days prior to
disease induction, with either 100 mg recombinant microbial heat shock protein 70 (HSP70) or 100 mg enhanced green fluorescent protein (EGFP)
both emulsified in synthetic adjuvant DDA or with PBS. Arthritis was induced by two immunizations of proteoglycan (PG) in DDA on day 0 and 21. (A)
Arthritis incidence is expressed as the cumulative percentage of arthritic animals and (B) arthritis severity is expressed as the mean arthritis score of
sick mice6SEM. Data are representative of three independent experiments (n=10 in each group).
doi:10.1371/journal.pone.0004186.g001
HSP70 Suppression in PGIA
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+CD25
+ cells were isolated from
the spleen on day 38 after the first PG injection. In this population
Foxp3 and IL-10 mRNA expression were analyzed by Quantita-
tive Real-Time PCR analysis showing that IL-10 mRNA
expression was increased in the CD4
+CD25
+ population from
HSP70 treated mice compared to PBS treated control mice (Fig. 5).
No clear difference in Foxp3 mRNA expression was observed,
between control and HSP70 immunized mice. This could be
Figure 2. Decreased leukocyte infiltration and cartilage breakdown in HSP70 immunized mice. PBS or heat shock protein 70 (HSP70)/
DDA immunization, followed by arthritis induction, was performed as described in figure 1. Upon sacrifice on day 35, histology of tarso-metatarsal
joints was done by staining of the sections with hematoxylin and eosin. (A) Synovial hyperplasia with infiltrating leukocytes, cartilage- (arrow heads)
and bone-erosions (arrows) can be seen. (B) In contrast, only a very few leukocytes, and no synovial cell proliferation or cartilage destruction were
observed in the joint sections of HSP70 immunized mice.
doi:10.1371/journal.pone.0004186.g002
Figure 3. Altered PG- and HSP70-specific B cell responses in
HSP70 immunized mice. Proteoglycan (PG)- or heat shock protein 70
(HSP70)-specific antibody production in the sera of mice was assessed
by ELISA and relative serum antibody levels were calculated as OD
relative to the OD measured for a standard of pooled sera. (A–B) PG-
specific IgG1 and IgG2a levels were determined (A) on day 38 and (B) on
day 50 or 64 after disease induction. (C) HSP70-specific total IgG
production was measured in sera obtained on day 38. Values in A and C
represent the mean6SEM (n=5 mice in each group) and are
representative for three independent experiments (PG-specific IgG) or
one experiment (HSP70-specific IgG). Values in B represent mean6SEM
(n=6 mice) of sera obtained on either day 50 or day 64, no obvious
difference between sera collected on day 50 or 64 was detected. Open
bars show the PBS immunized group and filled bars the HSP70
immunized group. Significant difference (* p,0.05 or **p,0.01, Mann-
Whitney U Test) is indicated by the asterisk.
doi:10.1371/journal.pone.0004186.g003
Figure 4. Augmented antigen-specific proliferation, IL-10 and
IFN-c production in HSP70 immunized mice. Mice were immu-
nized with PBS or heat shock protein 70 (HSP70) and arthritis was
induced as described in figure 1. Spleen cells were isolated on day 35
and cultured (2610
5/well) in the presence of recombinant microbial
HSP70, proteoglycan (PG) or ovalbumin (Ova) (all at 10 mg/ml). (A) After
96 hours incubation proliferation was determined by measuring
3H
incorporation. Results are expressed as mean stimulation index (CPM
Antigen/CPM background)6SEM. The mean background values (re-
sponses without antigen) were for the PBS control group 839062135
and for the HSP70 group 10 18062741. (B–C) For in vitro cytokine
secretion the spleen cells were cultured in the presence of antigen.
After 72 hours supernatants were harvested and assayed by multiplex
analysis for IL-10 and IFN-c excretion. Open bars show the PBS
immunized group and filled bars the HSP70 immunized group. Values
represent the mean6SEM of cytokine levels. Significant difference
(p,0.05, Mann-Whitney U Test) is indicated by the asterisk. Data are
representative for at least two independent experiments.
doi:10.1371/journal.pone.0004186.g004
HSP70 Suppression in PGIA
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Foxp3 protein expression (data not shown). Indicating that HSP70
does not increase the population of Foxp3 expressing regulatory T
cells.
IL-10 is important for the protective effects of HSP70
immunization
HSP70 immunization increased the antigen-specific IL-10
production suggesting that IL-10 is important for the anti-
inflammatory capacity of HSP70. To address whether protection
in arthritis by HSP70 immunization was indeed IL-10 dependent,
IL10
2/2 mice received 100 mg HSP70 or Ova as control i.p. in
DDA on day 210, followed by induction of arthritis by two
injections with PG in DDA on day 0 and day 21. HSP70
immunization of IL10
2/2 mice, in contrast to wild type mice
(WT), did not reduce arthritis severity as compared to control,
immunized IL10
2/2 mice. In addition, there was no obvious
difference in the mean maximum arthritis score or the day of onset
of disease (Table 1). To study the effect of HSP70 immunization,
in the absence of IL-10, on the B cell response, PG- and HSP70-
specific antibody production was measured in the sera of IL10
2/2
mice on day 53 after the first PG injection. Induction of arthritis
resulted in a clear PG-specific antibody response as shown by
elevated IgG1 and IgG2a levels in both treatment groups (Fig. 6A).
However, in parallel with the arthritis scores, HSP70 immuniza-
tion in IL-10
2/2 mice did not influence this PG-specific response.
As expected, HSP70 immunization enhanced the HSP70-specific
IgG production (Fig. 6B). Next, induction and modulation of the
antigen-specific T cell response by HSP70 treatment in IL-10
2/2
mice were addressed. Therefore, spleen cells were harvested on
day 53 followed by analysis of antigen-specific proliferation after in
vitro restimulation, for 72 hours with PG, Ova or HSP70.
3H
incorporation was depicted as stimulation index (CPM antigen/
CPM background). The mean background values (responses
without antigen) were for the PBS control group 17056339 and
for the HSP70 group 13946468. Similar to the response in WT
mice, immunization of IL10
2/2 mice with HSP70 enhanced the
proliferative response to HSP70 restimulation compared to control
immunization with Ova. But, it did not have an effect on PG-
specific proliferation (Fig. 6C). Furthermore, Ova specific
proliferation was slightly increased in mice that received Ova. In
addition, the effect of HSP70 immunization on antigen-specific
IFN-c secretion was studied, by ELISA in the culture superna-
tants. Also in IL10
2/2 mice, immunization with HSP70 increased
the production of IFN-c after HSP70 restimulation. But, the
enhanced PG-induced IFN-c production, observed in WT mice,
was not observed in IL10
2/2 mice (Fig. 6D). Taken together, this
indicated that HSP70 immunization of IL-10
2/2 mice induced an
HSP70-specific B and T cell response that, in the absence of IL-10,
failed to suppress PGIA development and PG-specific pathogenic
IgG2a production.
Discussion
The anti-inflammatory properties of HSP have been shown in
several studies in both animal models and in patients suffering
from inflammatory diseases [1,5,11,12,23,24]. However, for
further development of HSP for therapeutic application, it is
essential to understand the mechanisms by which HSP affect
chronic inflammatory disease in more detail. In this study we
analyzed the protective potential of HSP70 in PGIA, a chronic
model for RA, studied the T cell response induced by HSP70
immunization and addressed whether the presence of IL-10 was
essential. Our data clearly show that pretreatment with HSP70
delayed arthritis onset and dramatically reduced disease severity
both clinically and histologically. Furthermore, it increased the
antigen-specific T cell response to both the protective HSP70 and
the disease inducing PG. In IL-10 deficient mice HSP70
immunization did not suppress arthritis illustrating the IL-10
dependency of HSP70 induced immuno-regulation.
The immuno-regulatory effect of HSP70 immunization has
been demonstrated earlier in arthritis models in rats [9,25,26]. In
contrast to the rat models, the mouse PGIA model is a chronic and
progressive model of RA [27]. In addition, in this model arthritis
can be induced by immunization with proteoglycan mixed with
synthetic adjuvant DDA instead of CFA [18]. Therefore, the
Figure 5. Increased IL-10 mRNA expression in CD4
+CD25
+ cells
of HSP70 immunized mice. Mice were PBS or heat shock protein 70
(HSP70) immunized before induction of arthritis as described in figure 1.
On day 38, CD4
+CD25
+ cells were isolated from the spleen followed by
isolation of mRNA. Foxp3 and IL-10 mRNA expression was determined
by Quantitative Real-Time PCR analysis. Data are normalized and
expressed relative to HPRT and depicted as mean6SEM (n=5 mice in
each group). Significant difference (p,0.05, Mann-Whitney U Test) is
indicated by the asterisk.
doi:10.1371/journal.pone.0004186.g005




Mean day of onset Maximum arthritis score Mean day of onset Maximum arthritis score
control 3162.0 4.661.6 33.661.3 5.461.1
HSP70 5263.2 ** 1.160.3 * 33.060.0 4.261.4
Arthritis was induced in WT BALB/c (n=10 per group) or IL-10
2/2 mice (n=5 per group) by two immunizations with proteoglycan in the adjuvant DDA on days 0 and
day 21. Ten days prior to the induction of arthritis mice were immunized with 100 mg HSP70 whereas control mice received 100 mg EGFP or Ova. Subsequently,
development of arthritis symptoms was scored by clinical examination. Data are expressed as mean6SEM and are representative for at least two independent
experiments. * p,0.05 and ** p,0.01 (HSP70 immunized WT mice compared to control WT mice by Mann Whitney U test).
doi:10.1371/journal.pone.0004186.t001
HSP70 Suppression in PGIA
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terial HSP present in CFA can be excluded.
In the present study an HSP70-specific T cell response was
induced upon HSP70 immunization as detected by increased
proliferation, IL-10 and IFN-c production upon HSP70 in vitro
restimulation. Remarkably, also an enhanced PG-specific T cell
response, with a similar cytokine profile, was found in HSP70
immunized mice. This might be explained by HSP70 interaction
with innate receptors on antigen presenting cells, resulting in
enhanced antigen priming to the subsequent PG immunization.
Similarly, peptide-specific CD4
+ T cell proliferation has been
described to be enhanced when immunogenic peptides were fused
to HSP70 subsequently resulting in increased immunogenicity of
the peptides [28]. Alternatively, HSP70-induced regulatory T cells
might induce a tolerogenic micro-milieu, by their cytokine
production, enhancing the induction of regulatory T cells via
infectious tolerance. This has been shown to occur in other models
of autoimmunity in an IL-10 dependent manner [29].
Our data show that Hsp70 immunization induces a population
of IL-10 producing T cells that do not express enhanced levels of
Foxp3. Besides Foxp3 expressing CD25
+ T cells, additional
regulatory T cell subsets, such as adaptive Tr1, that do not
express high levels of Foxp3 constitutively, are known [30]. Tr1
cells are induced in the periphery upon encounter of antigen and
express high levels of IL-10 [31]. The HSP70-specifc IL-10
production together with enhanced IL-10 mRNA expression in
CD4
+CD25
+ T cells in HSP70 immunized mice suggests
activation or induction of HSP70-specific regulatory T cells.
However, our observation that also CD3
2 cells produce enhanced
levels of IL-10 in HSP70 immunized mice (data not shown)
indicates that multiple subsets of regulatory cells can contribute to
regulation and this remains to be elucidated. This is in contrast to
a recent study, where we showed an increase in Foxp3 expressing
regulatory T cells, after HSP treatment, in a mouse atherosclerosis
model [4]. However, in the present study CD4
+CD25
+ T cells
from HSP70 immunized mice did not increasingly express Foxp3,
indicating the possible presence of distinct types of regulation in
different models of inflammation.
B cell responses play an important role in the pathogeneses of
RA as demonstrated by the success of B cell targeted therapy, for
example with monoclonal antibodies like Rituximab, as recently
summarized [32]. Also in the PGIA model, B cells are important
for disease induction [17,33]. Therefore, the effect of HSP70
immunization on the B cell response was addressed by measuring
PG-specific IgG1 and IgG2a production. Interestingly, decreased
PG-specific IgG2a production was found in HSP70 immunized
mice, while the IgG1 levels were not significantly changed. In
earlier studies the IgG1 isotype has been shown to be the
dominant isotype in the PGIA model. However, in agreement with
our data, IgG2a levels have been described to correlate with
disease severity [34]. Furthermore, the IgG2a isotype is known to
be Th1 related. In accordance with these findings PGIA is
considered to be a Th1 mediated model. Thus our data indicate
that the pathogenic Th1 mediated PG-specific antibody response
was inhibited by HSP70 immunization. In contrast to the arthritis
associated PG-specific antibody response, HSP-specific antibodies
Figure 6. Protective effects found upon HSP70 immunization are IL-10 dependent. IL10
2/2 mice were immunized with ovalbumin (Ova) or
heat shock protein 70 (HSP70), subsequently arthritis was induced and scored as described in figure 1. (A) Proteoglycan (PG)-specific IgG1 and IgG2a
and (B) HSP70-specific total IgG production was measured by ELISA in sera obtained on day 52. Data in A and B are depicted relative to a standard of
pooled sera from either arthritic mice or HSP70 immunized mice. (C) Antigen-specific proliferation of spleen cells harvested on day 52 was measured
after 72 hours culturing in the presence of recombinant microbial HSP70, Ova or PG. Proliferation was measured by detection of
3H incorporation and
depicted as stimulation index (CPM Antigen/CPM background). The mean background values (responses without antigen) were for the PBS control
group 17056339 and for the HSP70 group 13946468. (D) After 72 hours incubation, antigen-induced IFN-c excretion in the culture supernatants was
analyzed by ELISA. Values represent the mean6SEM (n=5 mice in each group). Open bars show the Ova immunized group and filled bars the HSP70
immunized group. Significant difference (p,0.05, Mann-Whitney U Test) is indicated by the asterisk.
doi:10.1371/journal.pone.0004186.g006
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[21,22]. Therefore, the increased HSP70 IgG production found in
our study in HSP70 immunized mice might be important for the
regulatory potential of HSP70 treatment.
The increased HSP70-specifc B and T cell response, found in
WT mice after HSP70 immunization, was also found in IL-10
2/2
mice. However, in the absence of IL-10 this response failed to
suppress the pathogenic PG-specific B cell response and it did not
increase the PG-specific T cell response as observed in WT mice.
So, despite the induction of an obvious HSP70-specific response,
the protective effects of HSP70 immunization on the PG-specific B
and T cell response were shown to be IL-10 dependent,
consequently leading to development of severe arthritis in the
absence of IL-10. The important role of IL-10 in arthritis has been
studied previously in the PGIA model. In this study transfer of cells
expressing IL-10 after retroviral IL-10 gene transduction could
suppress arthritis [35]. Moreover, IL-10 has been described to
stimulate PG synthesis and to reverse cartilage degradation
induced by activated mononuclear cells [14] and it negatively
correlated with progression of joint destruction in RA [36],
showing the important anti-inflammatory function of IL-10 in
human RA.
Due to their stress inducible nature HSP can be ideal candidates
for immunotherapy against chronic inflammatory diseases like
RA. HSP will be upregulated, locally at the site of inflammation in
the joint, as reported previously [37–39]. Therefore, HSP-specific
immune responses can be targeted specifically to sites of
inflammation. Moreover, enhanced HSP-specific T cell responses
in patients have been described [5,6,40]. The observation that
such responses seemed to be associated with a benign form of
disease, which over time preceded disease remission [5,6], and the
fact that HSP-mediated preventive and therapeutic immune
interventions were effective in animal models of chronic
inflammatory diseases, suggests the immunotherapeutic potential
of HSP in patients with inflammatory autoimmune diseases.
In summary, this study shows that HSP70 can modulate
inflammation in a model for chronic and progressive arthritis
through IL-10 dependent mechanisms, operating via suppression
of pathogenic antibody responses and the development of
regulatory T cells. The chronic and progressive nature of the
model and the possibility to use specific knock out mice, like the
IL10
2/2 used in this study, will enable further mechanistic studies
needed for the development of HSP based immune intervention in
chronic inflammatory diseases.
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